(DPH.L) Dechra Pharmaceuticals PLC Buy/Sell

RNS Number : 1370C Dechra Pharmaceuticals PLC 06 November 2009

Date: 6 November 2009

Dechra® Pharmaceuticals PLC

(the "Company" or the "Group")

Results of Annual General Meeting ("AGM")

Dechra Pharmaceuticals PLC announces that all resolutions proposed at its AGM held on 6 November 2009 were duly passed on a show of hands.

Copies of the following:

RNS Number : 0715C
  Dechra Pharmaceuticals PLC
  06 November 2009
   

    

Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Friday, 6 November 2009

Dechra® Pharmaceuticals PLC

Interim Management Statement

Dechra Pharmaceuticals PLC ("Dechra" or the "Group"), which holds its Annual General Meeting today at 9.00am, publishes its Interim Management Statement covering the period from 1 July 2009 to the date of this announcement as required by the UK Listing Authority Disclosure and Transparency Rules.

The Group has started the financial year in line with management expectations with revenue in the first quarter 5.1% ahead of last year. There have been no material events or transactions during the relevant period and the financial position of the Group remains strong.

The Pharmaceuticals Division has continued to make good progress with first quarter revenue 11.0% higher than the equivalent period last year.  Vetoryl® sales into distributors in the US in the period were US$1.2 million. Sales into veterinary practices in the US are reflecting month on month growth and in September 2009 were almost US$0.5 million, a 25% increase over sales achieved in June 2009.

The Services Division achieved first quarter revenue growth of 3.3%.  National Veterinary Services® maintained its operating margin at the level achieved in the financial year ended 30 June 2009.

The Board remains confident that the Group will continue to make good strategic progress in line with management expectations throughout the remainder of the financial year.

 Enquiries:
 Ian Page, Chief Executive
 Simon Evans, Group Finance Director  Fiona Tooley, Director
 Dechra Pharmaceuticals PLC           Citigate Dewe Rogerson
 Tel: +44 (0)1782 771100              Tel: +44 (0)121 362 4035
 Mobile: + 44 (0)7775 642222 (IP)     Mobile: + 44 (0)7785 703523
 or + 44 (0)7775 642220 (SE)
 www.dechra.com
 corporate.enquiries@dechra.com

Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
IMSILFVRLDLEIIA

RNS Number : 6622B Dechra Pharmaceuticals PLC 30 October 2009

Dechra Pharmaceuticals PLC

(the "Company")

30 October 2009

In conformity with DTR 5.6.1R, the Company notifies the market of the following:

As at the date of this announcement, the Company's issued share capital consists of 65,243,909 Ordinary Shares with a nominal value of 1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of Ordinary Shares with voting rights is 65,836,052.

The above figure of 65,836,052 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

For further information

Zoe Goulding, Company Secretary

Telephone number: 01782 771100

This information is provided by RNS The company news service from the London Stock Exchange

TVRKBLBXKBBEFBV

RNS Number : 2928B Dechra Pharmaceuticals PLC 23 October 2009

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying Dechra
issuer of existing shares to which voting Pharmaceuticals Plc

rights are attached:

2 Reason for the notification (please tick the appropriate box or boxes):
Yes

An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify):

3. Full name of person(s) Legal & General Group
subject to the notification Plc (L&G)

obligation:

4. Full name of shareholder(s) Legal & General
(if different from 3.): Assurance (Pensions
Management) Limited

5. Date of the transaction and 21 October 2009

date on which the threshold is crossed or reached:

6. Date on which issuer 22 October 2009

notified:

7. Threshold(s) that is/are From 5% - 4% (L&G)

crossed or reached:

8. Notified details: A: Voting rights attached to shares

Class/type of Situation previous Resulting situation after the triggering transaction
shares to the triggering
transaction

if possible using the ISIN CODE
Number Number Number Number of voting % of voting
of of of shares rights rights
Shares Voting
Rights
Direct Direct Indirect Direct Indirect
ORD 3,859,762 3,859,762 3,270,269 3,270,269 4.98

GBP 0.01

B: Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that may be rights
Period acquired if the
instrument is
exercised/
converted.

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of financial Exercise Expiration Exercise/ Number of voting % of voting rights
instrument price date Conversion rights instrument
period refers to
Nominal Delta

Total (A+B+C)

Number of voting rights Percentage of voting rights
3,270,269 4.98

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: Legal & General Group Plc (Direct and Indirect) (Group) (3,987,412 * 6.07% = Total Position) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (3,987,412 * 6.07% = Total Position) Legal & General Investment Management Limited (Indirect) (LGIM) (3,987,412 * 6.07% = Total Position)
Legal & General Group Plc (Direct) (L&G) (3,270,269 * 4.98 % = LGAS,

LGPL & PMC)
Legal & General Investment Management (Holdings) Limited Legal & General
(Direct) (LGIMHD)(2,293,462 -3.49% =PMC) Insurance Holdings
Limited (Direct)

Legal & General Assurance (Pensions Management) Limited (PMC) Legal & General
(2,293,462 * 3.49% =PMC) Assurance Society
Limited (LGAS &

Legal & General
Pensions Limited
(Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A
13. Additional information: Notification using the total voting rights
figure of 65,588,924
14. Contact name: Helen Lewis (LGIM)
15. Contact telephone number: 020 3124 3851

This information is provided by RNS The company news service from the London Stock Exchange

HOLMGMZGGFMGLZM